American College of Clinical Pharmacy
      Search      Cart
         

Cardiology PRN Focus Session -- What’s New and Exciting in Cardiovascular Pharmacotherapy?

Tuesday, October 29, 2019 from 1:15 PM to 2:45 PM EST at 2nd Floor: Murray Hill

Available for 1.50 hours of CPE credit
Activity Number: 0217-0000-19-182-L01-P
Activity Type: A Knowledge-Based Activity


Speakers
  • William L. Baker, Jr., Pharm.D., FCCP, FACC, FAHAModerator: William L. Baker, Jr., Pharm.D., FCCP, FACC, FAHA
    Associate Professor of Pharmacy Practice, University of Connecticut School of Pharmacy, Storrs, Connecticut
      View Biography

How Should We Be Acutely Treating Ventricular Tachycardia in Patients with Structural Heart Disease?
1:15 PM

Speakers
  • C. Michael White, Pharm.D., R.Ph.,FCCPSpeaker: C. Michael White, Pharm.D., R.Ph.,FCCP
    Professor & Head, Department of Pharmacy Practice, University of Connecticut School of Pharmacy, Storrs, Connecticut
      View Biography

  • Kristen Bova Campbell, Pharm.D., BCPSSpeaker: Kristen Bova Campbell, Pharm.D., BCPS
    Clinical Pharmacist - Electrophysiology, Duke University Hospital Residency Director, PGY2 Cardiology Residency,Duke University Hospital
      View Biography


Learning Objectives
1. Compare the effectiveness and safety of intensifying antiarrhythmic drug therapy versus catheter ablation for the treatment of ventricular tachycardia resistant to standard antiarrhythmic drugs.
2. Devise a treatment strategy to optimally treat standard antiarrhythmic drug resistant ventricular tachycardia.
Should mTOR inhibitors Have a Prominent Role in Immunosuppression Regimens After Heart Transplantation?
1:40 PM

Speakers
  • Douglas L. Jennings, Pharm.D., FCCP, FAHA, FACC, BCPSSpeaker: Douglas L. Jennings, Pharm.D., FCCP, FAHA, FACC, BCPS
    Associate Professor, Department of Pharmacy Practice, Long Island University College of Pharmacy
      View Biography

  • Edward Horn, Pharm.D.Speaker: Edward Horn, Pharm.D.
    Associate Professor, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania


Learning Objectives
1. Describe the current evidence regarding the role of de Novo mTOR inhibitor use and calcineurin inhibitor minimization/replacement as a routine part of immunosuppression regimens after heart transplantation.
2. Examine the harms associated with the use of mTOR inhibitors as additions or replacements for calcineurin inhibitors after heart transplantation.
Balancing Thrombosis and Bleeding Risk in Patients with a Durable Ventricular Assist Device.
2:05 PM

Speakers
  • Ian B. Hollis, Pharm.D., BCPS-AQ CardiologySpeaker: Ian B. Hollis, Pharm.D., BCPS-AQ Cardiology
    Clinical Pharmacy Specialist, Cardiac Surgery & Advanced Heart Failure, University of North Carolina Medical Center, Chapel Hill, NC
      View Biography


Learning Objectives
1. Explain recent technological advances in ventricular assist devices and their associated thrombotic & bleeding risk.
2. Discuss the evidence supporting antithrombotic strategies with currently-available durable ventricular assist devices.
3. Devise a treatment strategy to minimize the risk of bleeding in patients with a durable ventricular assist device.
Question and Answer
2:30 PM